- Home
- PETZ vs APTO Comparison
PETZ vs APTO Comparison
Compare PETZ & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- APTO
- Stock Information
- Founded
- PETZ 2002
- APTO 1986
- Country
- PETZ China
- APTO Canada
- Employees
- PETZ N/A
- APTO N/A
- Industry
- PETZ Steel/Iron Ore
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETZ Industrials
- APTO Health Care
- Exchange
- PETZ Nasdaq
- APTO Nasdaq
- Market Cap
- PETZ 12.9M
- APTO 13.2M
- IPO Year
- PETZ 2017
- APTO N/A
- Fundamental
- Price
- PETZ $1.15
- APTO $0.16
- Analyst Decision
- PETZ
- APTO Strong Buy
- Analyst Count
- PETZ 0
- APTO 3
- Target Price
- PETZ N/A
- APTO $4.33
- AVG Volume (30 Days)
- PETZ 5.0K
- APTO 17.4M
- Earning Date
- PETZ 12-17-2024
- APTO 03-25-2025
- Dividend Yield
- PETZ N/A
- APTO N/A
- EPS Growth
- PETZ N/A
- APTO N/A
- EPS
- PETZ N/A
- APTO N/A
- Revenue
- PETZ $3,278,453.00
- APTO N/A
- Revenue This Year
- PETZ N/A
- APTO N/A
- Revenue Next Year
- PETZ N/A
- APTO N/A
- P/E Ratio
- PETZ N/A
- APTO N/A
- Revenue Growth
- PETZ 2.46
- APTO N/A
- 52 Week Low
- PETZ $1.01
- APTO $0.13
- 52 Week High
- PETZ $1.74
- APTO $1.94
- Technical
- Relative Strength Index (RSI)
- PETZ 44.66
- APTO 42.85
- Support Level
- PETZ $1.13
- APTO $0.13
- Resistance Level
- PETZ $1.23
- APTO $0.26
- Average True Range (ATR)
- PETZ 0.06
- APTO 0.02
- MACD
- PETZ -0.00
- APTO -0.00
- Stochastic Oscillator
- PETZ 16.67
- APTO 24.69
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.